閉経後膣萎縮治療の世界市場レポート2025年

閉経後膣萎縮治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.3％で31億3,000万米ドルに成長します。この将来的な成長の要因としては、更年期障害に特化したクリニックや婦人科受診の増加、個別化された患者別治療への嗜好の高まり、政府機関や健康関連機関からの支援の強化、ライフスタイルや医療介入による早期閉経の発生増加、市販薬やオンライン薬局のソリューションへのアクセス拡大などが挙げられます。予測期間中に予測される顕著な市場動向には、選択的エストロゲン受容体モジュレーター（SERM）の革新、デジタルヘルスツールと遠隔医療サービスの利用、ドラッグデリバリー技術の新たな進歩、非ホルモン治療戦略の進歩、低侵襲婦人科手術の改善などが含まれます。

閉経後人口の増加が、今後数年間の閉経後膣萎縮治療市場の成長を牽引すると予想されます。この母集団には、連続12ヵ月間月経がなく、生殖期の終わりを迎える女性が含まれます。平均寿命が延びるにつれて、より多くの女性が長生きするようになり、閉経後の段階でさらに長い年月を過ごすようになっています。閉経後の膣萎縮に対する治療は、エストロゲンレベルの低下によって引き起こされる乾燥や刺激などの症状を緩和することで、膣の健康を促進し、全体的な快適さと幸福感を向上させます。例えば、2022年10月のメイヨークリニックによると、世界の更年期および閉経後の女性の数は2030年までに12億人に達すると予測されており、毎年4,700万人の女性がこの段階に入ると推定されています。この人口層の増加が、市場の拡大に大きく寄与しています。

閉経後膣萎縮治療市場で事業を展開する企業は、エストラジオール膣インサートのような革新的なソリューションに注力し、的を絞った症状緩和を実現し、ホルモン療法のアドヒアランスを高めています。これらのインサートは、膣内に挿入する小型の装置で、局所的にエストロゲンを放出し、更年期障害により薄くなった膣組織の回復を助ける。全身への吸収を最小限に抑えながら、乾燥、かゆみ、不快感などの症状を効果的に緩和します。例えば、2024年1月、カナダに本社を置く製薬会社Knight Therapeutics社は、カナダ市場でIMVEXXYを発売しました。この製品は、閉経に伴う外陰部および膣の萎縮症状である中等度から重度の性交障害の治療に使用されます。4mcgまたは10mcgのエストラジオールを膣組織に直接投与し、粘膜の健康をサポートし、性交時の痛みを軽減します。インベクシーのユニークなソフトジェル製剤は、速溶性と血流への最小限の吸収を保証し、従来のエストロゲン治療に代わる、便利で、アプリケーター不要の、面倒のない選択肢を提供します。この技術革新は、閉経後の女性特有のニーズを満たす、患者の立場に立った治療法の開発に対する業界の献身を浮き彫りにするものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の閉経後膣萎縮治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の閉経後膣萎縮治療市場：成長率分析
• 世界の閉経後膣萎縮治療市場の実績：規模と成長, 2019-2024
• 世界の閉経後膣萎縮治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の閉経後膣萎縮治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の閉経後膣萎縮治療市場、治療テスト別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エストロゲンベースの薬
• 非エストロゲン系薬剤
• その他の治療法
• 世界の閉経後膣萎縮治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 膣内
• その他の投与経路
• 世界の閉経後膣萎縮治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の閉経後膣萎縮治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 婦人科
• 性的な健康
• 医薬品
• 世界の閉経後膣萎縮治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 在宅ケア
• 専門クリニック
• その他のエンドユーザー
• 世界の閉経後膣萎縮治療市場、エストロゲン系薬剤のテスト別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口エストロゲン療法
• 経皮エストロゲン療法
• エストロゲンインプラント
• 膣エストロゲン療法
• ブランド製品
• 世界の閉経後膣萎縮治療市場、非エストロゲン系薬剤のテスト別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的エストロゲン受容体モジュレーター
• プラステロン
• その他の非エストロゲンホルモン剤
• 世界の閉経後膣萎縮治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非薬物療法
• 市販薬

第7章 地域別・国別分析

• 世界の閉経後膣萎縮治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の閉経後膣萎縮治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 閉経後膣萎縮治療市場：競合情勢
• 閉経後膣萎縮治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Perrigo Company
• Shionogi & Co. Ltd.
• Hikma Pharmaceuticals
• Amneal Pharmaceuticals LLC
• Lupin Pharmaceuticals
• Mayne Pharma
• Upsher-Smith Laboratories
• Alvogen
• Ligand Pharmaceuticals Incorporated
• Dare Bioscience
• Millicent Pharma Limited
• TherapeuticsMD
• Bionovo Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 閉経後膣萎縮治療市場2029：新たな機会を提供する国
• 閉経後膣萎縮治療市場2029：新たな機会を提供するセグメント
• 閉経後膣萎縮治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Postmenopausal vaginal atrophy treatment includes both medical and therapeutic methods aimed at relieving symptoms like vaginal dryness, irritation, and discomfort caused by decreased estrogen levels following menopause. The primary objective is to restore vaginal tissue health, increase moisture and elasticity, and support improved sexual and urinary function. These treatments play a crucial role in preventing complications and greatly enhancing overall quality of life.

The primary categories of postmenopausal vaginal atrophy treatments consist of estrogen-based drugs, non-estrogen-based drugs, and other alternatives. Estrogen-based therapies serve as hormone treatments for addressing menopausal symptoms, promoting reproductive wellness, treating hormone-responsive cancers, and supporting gender-affirming care. These drugs can be administered through various methods, including oral, intravaginal, and others, and are available via multiple distribution channels such as hospital pharmacies, online platforms, and retail pharmacies. The treatments are used in diverse fields including gynecology, sexual wellness, and general pharmaceuticals, and cater to various end-users such as hospitals, home care setups, specialty clinics, and more.

The postmenopausal vaginal atrophy treatment market research report is one of a series of new publications from The Business Research Company that provides detailed insights into market statistics, including the global size of the postmenopausal vaginal atrophy treatment industry, regional market shares, competitive landscape, detailed market segmentation, current trends, growth opportunities, and any additional data needed to succeed in the industry. This report offers a comprehensive overview and an in-depth evaluation of both present conditions and future prospects within the market.

The postmenopausal vaginal atrophy treatment market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. Growth during the historical period has been influenced by factors such as a rising prevalence of postmenopausal symptoms, heightened awareness of vaginal health and menopause-related issues, an expanding global population of aging women, increased spending on women's healthcare, and a growing shift towards non-hormonal and localized treatment approaches.

The postmenopausal vaginal atrophy treatment market size is expected to see strong growth in the next few years. It will grow to $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. Contributing to this future growth are factors such as a rising number of menopause-focused clinics and gynecological consultations, increasing preference for personalized and patient-specific therapies, enhanced backing from governmental and health-focused organizations, a growing occurrence of early menopause driven by lifestyle and medical interventions, and wider accessibility of over-the-counter and online pharmacy solutions. Prominent market trends projected for the forecast period include innovations in selective estrogen receptor modulators (SERMs), the use of digital health tools and telehealth services, new advancements in drug delivery technologies, progress in non-hormonal treatment strategies, and improvements in minimally invasive gynecological procedures.

The increasing postmenopausal population is expected to drive the growth of the postmenopausal vaginal atrophy treatment market in the coming years. This population includes women who have not had a menstrual period for 12 consecutive months, marking the end of their reproductive phase. As life expectancy rises, more women are living longer and spending additional years in the postmenopausal stage. Treatments for postmenopausal vaginal atrophy help relieve symptoms such as dryness and irritation caused by decreased estrogen levels, thereby promoting vaginal health and improving overall comfort and well-being. For example, according to the Mayo Clinic in October 2022, the number of menopausal and postmenopausal women worldwide is projected to reach 1.2 billion by 2030, with an estimated 47 million women entering this stage each year. This growing demographic is contributing significantly to the expansion of the market.

Companies operating in the postmenopausal vaginal atrophy treatment market are focusing on innovative solutions like estradiol vaginal inserts to deliver targeted symptom relief and enhance adherence to hormone therapy. These inserts are small devices placed in the vagina that release estrogen locally, aiding in the restoration of thinning vaginal tissues due to menopause. They provide effective relief from symptoms such as dryness, itching, and discomfort with minimal systemic absorption. For instance, in January 2024, Knight Therapeutics, a pharmaceutical company based in Canada, launched IMVEXXY in the Canadian market. This product is used to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy associated with menopause. It delivers 4 mcg or 10 mcg of estradiol directly to vaginal tissues, supporting mucosal health and reducing pain during intercourse. IMVEXXY's unique softgel formulation ensures fast dissolution and minimal absorption into the bloodstream, offering a convenient, applicator-free, and mess-free alternative to traditional estrogen treatments. This innovation highlights the industry's dedication to developing patient-focused therapies that meet the specific needs of postmenopausal women.

In June 2023, Cosette Pharmaceuticals, a US-based pharmaceutical firm, acquired Intrarosa from Endoceutics Inc. for an undisclosed amount. This acquisition aims to enhance Cosette's women's health portfolio by incorporating a differentiated, patent-protected, commercially available product for the treatment of moderate-to-severe dyspareunia due to menopause. The move reinforces Cosette's commitment to women's health and expands its global reach, utilizing its commercial and manufacturing expertise to maintain patient access to Intrarosa. Endoceutics Inc. is a US-based provider of treatments for postmenopausal vaginal atrophy.

Major players in the postmenopausal vaginal atrophy treatment market are Pfizer Inc., AbbVie Inc., Bayer AG, Novartis AG, Novo Nordisk A/S, Viatris Inc., Teva Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Hikma Pharmaceuticals, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Mayne Pharma, Upsher-Smith Laboratories, Alvogen, Ligand Pharmaceuticals Incorporated, Dare Bioscience, Millicent Pharma Limited, TherapeuticsMD, and Bionovo Inc.

North America was the largest region in the postmenopausal vaginal atrophy treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in postmenopausal vaginal atrophy treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the postmenopausal vaginal atrophy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The postmenopausal vaginal atrophy treatment market consists of revenues earned by entities by providing services such as medical consultation and diagnosis, hormonal therapy administration, patient education and counseling, and follow-up and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The postmenopausal vaginal atrophy treatment market also includes sales of vaginal gels, creams, tablets, patches, and rings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Postmenopausal Vaginal Atrophy Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on postmenopausal vaginal atrophy treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for postmenopausal vaginal atrophy treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The postmenopausal vaginal atrophy treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: Estrogen Based Drugs; Non-Estrogen Based Drugs; Other Therapy Types
• 2) By Route Of Administration: Oral; Intravaginal; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 4) By Application: Gynecology; Sexual Health; Pharmaceuticals
• 5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Estrogen Based Drugs: Oral Estrogen Therapy; Transdermal Estrogen Therapy; Estrogen Implants; Vaginal Estrogen Therapy; Branded Products
• 2) By Non-Estrogen Based Drugs: Selective Estrogen Receptor Modulators; Prasterone; Other Non-Estrogen Hormonal Agents
• 3) By Other Therapy Types: Non-Drug Therapies; Over-The-Counter Products
• Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Postmenopausal Vaginal Atrophy Treatment Market Characteristics

3. Postmenopausal Vaginal Atrophy Treatment Market Trends And Strategies

4. Postmenopausal Vaginal Atrophy Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Postmenopausal Vaginal Atrophy Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Postmenopausal Vaginal Atrophy Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Postmenopausal Vaginal Atrophy Treatment Market Growth Rate Analysis
• 5.4. Global Postmenopausal Vaginal Atrophy Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Postmenopausal Vaginal Atrophy Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Postmenopausal Vaginal Atrophy Treatment Total Addressable Market (TAM)

6. Postmenopausal Vaginal Atrophy Treatment Market Segmentation

• 6.1. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Estrogen Based Drugs
• Non-Estrogen Based Drugs
• Other Therapy Types
• 6.2. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravaginal
• Other Routes Of Administration
• 6.3. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.4. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gynecology
• Sexual Health
• Pharmaceuticals
• 6.5. Global Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Postmenopausal Vaginal Atrophy Treatment Market, Sub-Segmentation Of Estrogen Based Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Estrogen Therapy
• Transdermal Estrogen Therapy
• Estrogen Implants
• Vaginal Estrogen Therapy
• Branded Products
• 6.7. Global Postmenopausal Vaginal Atrophy Treatment Market, Sub-Segmentation Of Non-Estrogen Based Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators
• Prasterone
• Other Non-Estrogen Hormonal Agents
• 6.8. Global Postmenopausal Vaginal Atrophy Treatment Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Drug Therapies
• Over-The-Counter Products

7. Postmenopausal Vaginal Atrophy Treatment Market Regional And Country Analysis

• 7.1. Global Postmenopausal Vaginal Atrophy Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Postmenopausal Vaginal Atrophy Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market

• 8.1. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Postmenopausal Vaginal Atrophy Treatment Market

• 9.1. China Postmenopausal Vaginal Atrophy Treatment Market Overview
• 9.2. China Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Postmenopausal Vaginal Atrophy Treatment Market

• 10.1. India Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Postmenopausal Vaginal Atrophy Treatment Market

• 11.1. Japan Postmenopausal Vaginal Atrophy Treatment Market Overview
• 11.2. Japan Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Postmenopausal Vaginal Atrophy Treatment Market

• 12.1. Australia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Postmenopausal Vaginal Atrophy Treatment Market

• 13.1. Indonesia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Postmenopausal Vaginal Atrophy Treatment Market

• 14.1. South Korea Postmenopausal Vaginal Atrophy Treatment Market Overview
• 14.2. South Korea Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Postmenopausal Vaginal Atrophy Treatment Market

• 15.1. Western Europe Postmenopausal Vaginal Atrophy Treatment Market Overview
• 15.2. Western Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Postmenopausal Vaginal Atrophy Treatment Market

• 16.1. UK Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Postmenopausal Vaginal Atrophy Treatment Market

• 17.1. Germany Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Postmenopausal Vaginal Atrophy Treatment Market

• 18.1. France Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Postmenopausal Vaginal Atrophy Treatment Market

• 19.1. Italy Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Postmenopausal Vaginal Atrophy Treatment Market

• 20.1. Spain Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market

• 21.1. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market Overview
• 21.2. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Postmenopausal Vaginal Atrophy Treatment Market

• 22.1. Russia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Postmenopausal Vaginal Atrophy Treatment Market

• 23.1. North America Postmenopausal Vaginal Atrophy Treatment Market Overview
• 23.2. North America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Postmenopausal Vaginal Atrophy Treatment Market

• 24.1. USA Postmenopausal Vaginal Atrophy Treatment Market Overview
• 24.2. USA Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Postmenopausal Vaginal Atrophy Treatment Market

• 25.1. Canada Postmenopausal Vaginal Atrophy Treatment Market Overview
• 25.2. Canada Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Postmenopausal Vaginal Atrophy Treatment Market

• 26.1. South America Postmenopausal Vaginal Atrophy Treatment Market Overview
• 26.2. South America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Postmenopausal Vaginal Atrophy Treatment Market

• 27.1. Brazil Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Postmenopausal Vaginal Atrophy Treatment Market

• 28.1. Middle East Postmenopausal Vaginal Atrophy Treatment Market Overview
• 28.2. Middle East Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Postmenopausal Vaginal Atrophy Treatment Market

• 29.1. Africa Postmenopausal Vaginal Atrophy Treatment Market Overview
• 29.2. Africa Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Postmenopausal Vaginal Atrophy Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Postmenopausal Vaginal Atrophy Treatment Market Competitive Landscape And Company Profiles

• 30.1. Postmenopausal Vaginal Atrophy Treatment Market Competitive Landscape
• 30.2. Postmenopausal Vaginal Atrophy Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Postmenopausal Vaginal Atrophy Treatment Market Other Major And Innovative Companies

• 31.1. Viatris Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Perrigo Company
• 31.4. Shionogi & Co. Ltd.
• 31.5. Hikma Pharmaceuticals
• 31.6. Amneal Pharmaceuticals LLC
• 31.7. Lupin Pharmaceuticals
• 31.8. Mayne Pharma
• 31.9. Upsher-Smith Laboratories
• 31.10. Alvogen
• 31.11. Ligand Pharmaceuticals Incorporated
• 31.12. Dare Bioscience
• 31.13. Millicent Pharma Limited
• 31.14. TherapeuticsMD
• 31.15. Bionovo Inc.

32. Global Postmenopausal Vaginal Atrophy Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Postmenopausal Vaginal Atrophy Treatment Market

34. Recent Developments In The Postmenopausal Vaginal Atrophy Treatment Market

35. Postmenopausal Vaginal Atrophy Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Postmenopausal Vaginal Atrophy Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Postmenopausal Vaginal Atrophy Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Postmenopausal Vaginal Atrophy Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer